Kansas City, KSNCT07625579Now EnrollingIRB Ready

Down Syndrome Clinical Trial in Kansas City, KS

Access cutting-edge down syndrome treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by RTI International

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access down syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related down syndrome treatment provided free

Apply for This Kansas City Location

Check if you qualify for this down syndrome clinical trial in Kansas City, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Down Syndrome Study in Kansas City

The Collaboration for Down Syndrome Progress (CDP) is a long-term study that follows people with Down syndrome of all ages. The goal is to better understand their health, development, and everyday experiences over time. Participants and their caregivers will answer questions, share medical information, and may give samples like blood or saliva. Some participants may also take part in optional activities such as sleep studies, movement tracking, or brain imaging. By collecting the same types of information at many sites, the CDP will help researchers learn why certain health conditions are more common in people with Down syndrome and how to improve care and quality of life.

Sponsor: RTI International

Who Can Participate

Inclusion Criteria

Individual with Down syndrome To be considered potentially eligible for this CDP, a participant must meet the following criteria:
Diagnosis of Down syndrome (with the exception of control participants for the Subsample study on Imaging). We will be enrolling participants with all types of Down syndrome including standard Trisomy 21, mosaic Down syndrome, and translocations.
Primary language is English, Spanish, or Portuguese. Support Person
Able to attend in-person or remote visits.
Able to provide accurate information about the study participant's clinical outcomes and family history.
Primary language is English, Spanish, or Portuguese. Biological parent(s) biospecimen collection
Biological parent of the enrolled participant.
Willing to provide a biological sample.
Primary language is English, Spanish, or Portuguese. Imaging subsample study controls
A subset of controls will be enrolled to match a cohort of individuals who take part in the CDP Subsample Study on imaging. Healthy control infants must be born at greater than 36 weeks gestational age and must have at least one older sibling. The sibling criterion allows comparability for potential analyses combining control data from DS-CDP with analogous control data previously collected by IBIS for other neurodevelopmental studies.

Exclusion Criteria

A participant will also be excluded if a healthcare professional determines that CDP involvement poses a risk of mental and physical harm to the participant. Imaging subsample study exclusion criteria for individuals with Down syndrome and controls:
Known genetic conditions or syndromes with effects on neurobehavioral development (except for Down syndrome) such as Fragile X syndrome, Williams syndrome, or Prader-Willi syndrome. We may also exclude other syndromes such as Marfan's syndrome or Turner syndrome because of overall significant multisystem effects.
Birth weight \< 2,000 grams or gestational age \< 34 weeks (infants with Down syndrome infants) or \<37 weeks (control subjects)
Significant perinatal adversity, in utero neurotoxin exposure or maternal gestational diabetes requiring medication management
Significant medical conditions (unrelated to Down syndrome) affecting growth, development, cognition or sensory impairments. We will conduct a review of the medical history to identify major medical conditions that might be a reason for exclusion.
Neurological event like a stroke
Congenital infection associated with altered development (e.g., congenital rubella)
Significant infection affecting the brain after birth, like meningitis
In infants with Down syndrome, severe medical issues which may exert significant developmental effects beyond Down syndrome such as:
Cyanotic cardiac abnormalities (e.g., Tetralogy of Fallot) that affect overall oxygen levels
Frailty because of recovery from significant surgery or extended hospital stays
Contraindication for MRI
English not predominant home language
Family history of a first-degree relative with psychosis or bipolar disorder (controls only)
To be consistent with prior imaging studies from the infant brain imaging study, healthy controls will additionally be excluded for a family history of a first- or second-degree relative with ASD to also allow them to serve as a comparison group for elevated familial liability for ASD. Sleep subsample study exclusion criteria:
Participants under the age of 12 who are currently being treated for obstructive sleep apnea using a positive airway pressure (PAP) device.
For the WatchPAT device, participants must weigh more than 65 pounds. They cannot have a permanent pacemaker or sustained non-sinus cardiac arrhythmias.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT07625579) has an active research site in Kansas City, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Down Syndrome Treatment Options in Kansas City, KS

If you're searching for down syndrome treatment options in Kansas City, KS, this clinical trial (NCT07625579) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced down syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all down syndrome clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Kansas City, KS

See all myalgic encephalomyelitis clinical trials recruiting in Kansas City — not just this study.

Browse Myalgic Encephalomyelitis Trials in Kansas City →

Browse More Trials by Condition

Myalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, KS